1 week Ago
Senores Pharmaceuticals IPO received a healthy response from investors with an overall subscription of 13 times on the first two days of bidding. This was largely driven by retail and non-institutional investors, while the institutional ones stayed away. Check price band for Senores Pharmaceuticals IPO The company has fixed a price band of Rs 372-391 per share, where investors can bid for 38 shares in one lot and in multiples thereafter.
Here is the GMP of Senores Pharmaceuticals IPO today Senores Pharmaceuticals was commanding a GMP of Rs 230, which indicates a premium of 58% over the issue price. 8 billion dollar IPO debuts that fell below the mark, burning investor pockets Stock Trading A2Z of Stock Trading - Online Stock Trading Course By - elearnmarkets, Financial Education by StockEdge View Program Stock Trading Renko Chart Patterns Made Easy By - Kaushik Akiwatkar, Derivative Trader and Investor View Program Stock Trading Derivative Analytics Made Easy By - Vivek Bajaj, Co Founder- Stockedge and Elearnmarkets View Program Stock Trading Technical Analysis Demystified: A Complete Guide to Trading By - Kunal Patel, Options Trader, Instructor View Program Stock Trading Ichimoku Trading Unlocked: Expert Analysis and Strategy By - Dinesh Nagpal, Full Time Trader, Ichimoku & Trading Psychology Expert View Program Stock Trading Algo Trading Made Easy By - Vivek Gadodia, Partner at Dravyaniti Consulting and RBT Algo Systems View Program Stock Trading Stock Investing Made Easy: Beginner's Stock Market Investment Course By - elearnmarkets, Financial Education by StockEdge View Program Stock Trading RSI Made Easy: RSI Trading Course By - Souradeep Dey, Equity and Commodity Trader, Trainer View Program Stock Trading Complete Guide to Stock Market Trading: From Basics to Advanced By - Harneet Singh Kharbanda, Full Time Trader View Program Stock Trading Stock Valuation Made Easy By - Rounak Gouti, Investment commentary writer, Experience in equity research View Program Stock Trading Options Scalping Made Easy By - Sivakumar Jayachandran, Ace Scalper View Program Stock Trading Introduction to Technical Analysis & Candlestick Theory By - Dinesh Nagpal, Full Time Trader, Ichimoku & Trading Psychology Expert View Program Stock Trading Market 101: An Insight into Trendlines and Momentum By - Rohit Srivastava, Founder- Indiacharts.com View Program Stock Trading Dow Theory Made Easy By - Vishal Mehta, Independent Systematic Trader View Program Review of Senores Pharmaceuticals IPO Analysts advised investors to subscribe to the issue as the valuations are attractive and the demand for pharmaceuticals remains high.
At the upper price band, the company is valued at P/E of 55x with a market cap of Rs 1801 crore post issue of equity shares and return on net worth of 23.6% based on FY24. "On the valuation front, we believe that the company is fairly priced.
Therefore, we recommend a subscribe rating to the IPO," said Anand Rathi. About Senores Pharma IPO Senores Pharmaceuticals is a global research-driven pharmaceutical company focused on developing and manufacturing a wide range of pharmaceutical products, mainly for the regulated markets in the US and Canada. The company's product portfolio consists of Amphetamine Sulfate Tablets, Hydroxychloroquine Sulfate Tablets, Ketoconazole Tablets, Butalbital, Acetaminophen and Caffeine Capsules, Mexiletine Hydrochloride Capsules among others.
Also Read: Unimech Aerospace IPO. Check GMP, review, other details As of September 2024, it has launched 55 products in key therapeutic areas, including antibiotics and anti-fungal treatments. They have established partnerships with distributors and hospitals across several states in India.
Senores Pharma operates in emerging markets across 43 countries and manufactures critical care injectables and APIs. The company operates three dedicated R&D facilities in India and the US. In FY24, the company's revenues and profit grew multifold to Rs 217 crore and Rs 32.
7 crore, respectively. When is the allotment and listing Date of Senores Pharma IPO? Senores Pharma IPO opened up for public subscription on December 20 with the issue closing on December 24. Meanwhile, the allotment for the IPO is expected to be finalised on December 26 and the listing of shares will be on December 30.
( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times) ET Year-end Special Reads An Indian's guide to moving abroad as the world looks for 'better' immigrants The year of the HNIs: How India's rich splurged in 2024 (You can now subscribe to our ETMarkets WhatsApp channel ).
